Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Abstract Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these changes. This planned interim analysis reports the gastrointestinal and genitourinary...

Full description

Bibliographic Details
Main Authors: Julian O. Kim, Megan O. McDonald, Aldrich Ong, Rashmi Koul, Arbind Dubey, William Hunter, Shahida Ahmed, Harvey Quon, Don Yee, Matthew Parliament, Gokulan Sivananthan, Brita Danielson, Lindsay Rowe, Sunita Ghosh, Nawaid Usmani
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Radiation Oncology
Subjects:
Metformin
Prostate cancer
Gastrointestinal toxicity
Genitourinary toxicity
Online Access:https://doi.org/10.1186/s13014-021-01935-x

Internet

https://doi.org/10.1186/s13014-021-01935-x

Similar Items